Clinical Research Directory
Browse clinical research sites, groups, and studies.
Tau PET Outcomes With Anti-amyloid Immunotherapies
Sponsor: Mayo Clinic
Summary
This is an imaging study of patients with mild Alzheimer's disease receiving amyloid-targeting therapy and under the care of neurologists at Mayo Clinic in Rochester, MN.
Official title: Study of Tau PET Outcomes in Patients Receiving Anti-amyloid Immunotherapies
Key Details
Gender
All
Age Range
50 Years - 90 Years
Study Type
INTERVENTIONAL
Enrollment
135
Start Date
2025-11-04
Completion Date
2028-08
Last Updated
2026-10-30
Healthy Volunteers
No
Interventions
18F-AV-1451
Subjects will receive two Tau PET (18F--AV-1451) brain scans with approximately 10 mCi (370 MBq) (+/- 10%mCi) of 18F-AV-1451. Images will be collected for a 20-minute acquisition between 80-100 minutes after injection. Tau PET scans will occur at baseline and 12-18 months after completing anti-amyloid immunotherapy treatment..
C-11 ER-176
For the optional TSPO PET scans, C-11 ER176 will be administered as a single time IV injection prior to PET imaging. The injected dose of C-11 ER176 will be 518 MBq (14 mCi) (range 370-666 MBq; 10-18 mCi).
Locations (1)
Mayo Clinic
Rochester, Minnesota, United States